Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
Spruce Biosciences stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Spruce Biosciences balance sheet

Report period2018 2019 2020 2021 2022Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Spruce Biosciences cash flows

Report period2018 2019 2020 2021 2022Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Spruce Biosciences multipliers

Report period2018 2019 2020 2021 2022Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Spruce Biosciences profitability

Report period2018 2019 2020 2021 2022Q3 23 TTM
ROA
ROE
ROS
EBITDA Margin
Operating margin
Spruce Biosciences assets
Spruce Biosciences cash flows

Spruce Biosciences dividend policy

The company doesn't provide dividend

Spruce Biosciences shares

TickerNameTypeNominal valueISINPrice
SPRB:USSpruce BiosciencesCommon share-US85209E1091$0.4957
Spruce Biosciences news
15.03.2022
Spruce Biosciences' GAAP loss for 2021 was $42.292 million, up 43.2% from $29.539 million the previous year.
Source: {source} pictogram investors.sprucebiosciences.com
Pictogram next
11.08.2021
Spruce Biosciences' GAAP loss for 6M 2021 was $21.661 million, up 86.5% from $11.614 million in the previous year.
Source: {source} pictogram investors.sprucebiosciences.com
Pictogram next
13.05.2021
Spruce Biosciences' GAAP loss for 3 months of 2021 was $9.887 million, up 91.3% from $5.168 million in the previous year.
Source: {source} pictogram investors.sprucebiosciences.com
Pictogram next
23.03.2021
Spruce Biosciences' GAAP loss for 2020 was $29.539 million, up 2.3 times from $13.088 million in the previous year.
Source: {source} pictogram investors.sprucebiosciences.com
Pictogram next
All Spruce Biosciences news
General information
Company nameSpruce Biosciences
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address2001 Junipero Serra Boulevard Suite 640 Daly City, CA 94014 United States
Websiteinvestors.sprucebiosciences.com
Information disclosurewww.sec.gov